Research programme: phosphodiesterase inhbitors - Intra-Cellular TherapiesAlternative Names: ITI 002 series; PDE1 inhbitors - Intra-Cellular Therapies; PDE2 inhibitors - Intra-Cellular Therapies; PDE9 inhibitors - Intra-Cellular Therapies
Latest Information Update: 05 Nov 2014
At a glance
- Originator Intra-Cellular Therapies
- Class Small molecules
- Mechanism of Action Phosphodiesterase 9A inhibitors; Type 1 cyclic nucleotide phosphodiesterase inhibitors; Type 2 cyclic nucleotide phosphodiesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders; Neurodegenerative disorders
- Research Alzheimer's disease; Schizophrenia